Finance

Beta
Lists
KLRS:NASDAQ
Kalaris Therapeutics Inc
$4.04
-4.15%
(-0.18) 1D
Jun 30, 3:00:22 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KLRS...
Open
$4.24
High
$4.34
Low
$4.04
Mkt. cap
96.12M
Avg. vol.
78.72K
Volume
36.42K
52-wk high
$11.88
52-wk low
$2.14
EPS
-$2.21
Beta
0.15
Shares outstanding
23.79M
No. of employees
20
Open
$4.24
High
$4.34
Low
$4.04
Mkt. cap
96.12M
Avg. vol.
78.72K
Volume
36.42K
52-wk high
$11.88
52-wk low
$2.14
EPS
-$2.21
Beta
0.15
Shares outstanding
23.79M
No. of employees
20
News stories
From sources across the web
About Kalaris Therapeutics Inc
CEO-
Employees20
Founded2019
HeadquartersBerkeley Heights, New Jersey, United States
SectorBiotechnology
Websitekalaristx.com
Analyst ratings
Based on 5 analysts giving stock ratings to KLRS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KLRS in the last 3 months.
Highest
Current $4.04
$25.00 (+518.81%)
Average
$18.67 (+362.13%)
Lowest
$14.00 (+246.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tara Bancroft
TD Cowen
Buy
Initiated
-
-
06/15/2026
Yun Zhong
Wedbush
Buy
Maintained
$17.00
+320.8%
06/01/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$14.00
+246.5%
05/13/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$25.00
+518.8%
05/13/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
05/12/2026
Biren Amin
Piper Sandler
Hold
Maintained
$7.00
+73.3%
03/30/2026
Daniil Gataulin
Chardan Capital
Buy
Initiated
$19.00
+370.3%
12/23/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.44M
9.13M
7.16M
7.57M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.82M
3.62M
3.64M
4.26M
Operating expense
12.26M
12.74M
10.80M
11.83M
Total operating expenses
12.26M
12.74M
10.80M
11.83M
Operating income
-12.26M
-12.74M
-10.80M
-11.83M
Other non operating income
906.00K
847.00K
803.00K
977.00K
EBT including unusual items
-11.35M
-11.89M
-10.00M
-10.86M
EBT excluding unusual items
-11.35M
-11.89M
-10.00M
-10.86M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.35M
-11.89M
-10.00M
-10.86M
Net profit margin
-
-
-
-
Earnings per share
-0.61
-0.64
-0.44
-0.46
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-12.74M
-10.79M
-11.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer